Additional Programs

The melanocortin system can be leveraged for much more than optimizing body weight. Beyond obesity and cachexia, Kalohexis’ pipeline includes first-in-class MC4R-selective and MC3R-selective agonists with the potential to address multiple high-value and underserved metabolic indications, including type 2 diabetes, metabolic dysfunction-associated steatohepatitis, opioid use disorder, sarcopenia, polycystic ovary syndrome, muscle retention adjuvant, and menopausal weight maintenance.